TMC
CAPR icon

Trellus Management Company’s Capricor Therapeutics CAPR Stock Holding History

Trellus Management Company’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-270,000
Closed -$1.26M – 66
2021
Q1 		$1.26M Buy
+270,000
New +$1.56M 0.65% 29

Other funds holding CAPR

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Trellus Management Company's CAPR Position: Q2 2021 in Review

Trellus Management Company sold out of Capricor Therapeutics (CAPR) in Q2 2021, closing a stake of 270,000 shares — an estimated $1.26M sold.

Trellus Management Company first reported a position in CAPR in Q1 2021 and held it in 1 quarter. The position peaked at $1.26M in Q1 2021. 31 funds tracked by Wall St. Rank hold CAPR as of Q2 2021.

  • Trellus Management Company reported no remaining Capricor Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Trellus Management Company sold 270,000 Capricor Therapeutics shares in Q2 2021, an estimated $1.26M.
  • Trellus Management Company first reported a position in Capricor Therapeutics in Q1 2021 and held it in 1 quarter.
  • Trellus Management Company's Capricor Therapeutics position peaked at $1.26M in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2021.

Based on Trellus Management Company's 13F filing for Q2 2021, filed 30 Jul 2021.